Here, we utilize the NanoString‐based nCounter PanCancer Immune Profiling PanelTM (18), quantifying the expression levels of 770 genes related to immune‐oncological signaling pathways and cell types to characterize muscle biopsies from DM patients harboring anti‐TIF‐1γ and anti‐Mi‐2 autoantibodies, to see if any DM‐specific subgroups may be differentiated using an alternative molecular technique. Here, TRIM33 is linked to dermatomyositis.